Molekulare Pathogenese maligner Lymphome

Leitung

Prof. Dr. M. Dreyling

 

Forschungsprojekte / Forschungsschwerpunkte

  • Molekulare Pathogenese maligner Lymphome

 

Publikationen

  • Aukema SM, et al. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network. Blood. 2018 Jan 25;131(4):417

  • Hellmuth JC, et al. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood. 2018 Oct 18;132(16):1695

  • Zoellner AK, Peter N, Zimmermann Y, Hutter G, Hiddemann W, Dreyling M. Transient Antagonism of anti-CD20 monoclonal Antibodies and PI3K Inhibitor Idelalisib in DLBCL cell lines. Eur J Haematol. 2018 Apr 4.

  • Rauert-Wunderlich H, et al. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. Br J Haematol. 2019 Feb;184(4):616-624

  • Zhou X, et al. The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma.  Front Oncol. 2020 May 27;10:682

 

Mitarbeiter

  • J. Deuss (cand. Dr. med.)

  • V. Hoffmann (cand. Dr. med.)

  • D. Huber (cand. Dr. vet.)

  • N. Mack (cand. Dr. med.)

  • A. Schanda (cand. Dr. med.)

  • C. Schwandner (cand. Dr. med.)

  • Dr. E. Silkenstedt

  • Y. Zimmermann (MTA)

  • Dr. A. Zöllner

 

Kontakt

Prof. Dr. M. Dreyling

Klinikum der Universität München - Campus Großhadern

Marchioninistraße 15

D-81377 München

Telefon (089) 4400 - 72202
Fax (089) 4400 - 72201
E-Mail martin.dreyling@med.uni-muenchen.de

 

  Verantwortlich für den Inhalt: Prof. Dr. M. Dreyling; Stand: 15.04.2018